A Phase 3 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 20 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-31.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 19th largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 20th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 20th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2014, is one of 10 in phase 3, and was the 28th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
This study will assess the effect of a 24-week withdrawal followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with stable low systemic lupus erythematosus (SLE) disease activity. Rebound phenomenon will be assessed for subjects who have permanently withdrawn from further belimumab treatment.
This study will assess the effect of a 24-week withdrawal of belimumab followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications on immunogenicity, markers of biological activity, efficacy, and safety in subjects with stable low systemic lupus erythematosus (SLE) disease activity. Additionally, this study will assess rebound phenomenon in subjects with any disease level of SLE who have permanently withdrawn from further belimumab treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
Drug: Belimumab
Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
Drug: Belimumab
Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
Monthly intravenous infusions dosed as 10 mg/kg body weight
Median Time to First SLE Flare Index (SFI)
SFI Flare was defined as a mild/moderate or severe flare according to the modified Safety of Estrogen in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) SLE Flare Index (modified excluded severe flares from the SELENA SLEDAI flare assessment that were triggered only by an increase in SELENA SLEDAI score to \>12).Time to first SFI flare is defined as the number of days from Day 0 visit date to the date the participant has a flare (event date - Day 0 visit date + 1) in the 52 Week/Holiday phase; (event date - treatment re-start date + 1) in the Re-start Holiday phase. Day 0 visit date is defined as Day 0 from present study. Median time to first SFI flare is reported; estimated using the product-limit method.
Time frame: Up to 52 weeks
Rate of SLE Index Flare Per Subject Year
Rate per subject year of SFI flare was calculated as total number of flares divided by total subject years in interval. The total subject years for each participant was calculated as (Week 52/ Exit visit date minus Day 0 visit date + 1) for Long-term discontinuation and treatment control groups. For treatment holiday phase group the subject-years for each participant was calculated as (Week 24/Treatment Re-start/Exit visit date minus Day 0 Visit date + 1)/365.25. For re-start treatment holiday phase group the subject-years for each participant was calculated as (Week 52/Exit visit date minus Week 24/Treatment Re-start date + 1)/365.25. Day 0 visit date is defined as Day 0 from present study.
Time frame: Up to 52 weeks
Median Time to First Severe SFI Flare
The SLE Flare Index categorizes SLE flare as "mild or moderate" or "severe" based on a positive assessment for at least 1 of 5 variables as follows: Change in SELENA SLEDAI score from the most recent assessment to current; Change in signs or symptoms of disease activity; Change in prednisone dosage; Use of new medications for disease activity or hospitalization; Change in Physician's Global Assessment (PGA) score; Hospitalization for SLE activity is an additional category included only for a severe flare. Time to first severe flare is defined as (event date-Day 0 visit date) + 1 for Long-term discontinuation, treatment control groups and holiday phase group. For holiday phase group data censored at last flare assessment by treatment re-start date. Time to first severe flare is defined as (event date-treatment re-start date) + 1 for Re-start treatment holiday group. Median time to first severe SFI flare is reported; estimated using the product-limit method.
Time frame: Up to 52 weeks
Number of Participants With Evidence of Rebound
Rebound is defined as SELENA SLEDAI score during the first 24 weeks that exceeds the Baseline SELENA SLEDAI score in the participant's respective original parent study. Baseline is defined as the Day 0 visit from the parent study. SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, laboratory tests, and physician's assessment for each of 9 organ systems are given a weighted score and summed if present (marked 'Yes') at the time of the visit or in the preceding 10 days. The maximum theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 'No'). Any time during the first 24 weeks of this study has been reported.
Time frame: Up to 24 weeks
Number of Participants With Confirmed True Positive Belimumab Anti-drug Antibodies (ADA)
Immunogenicity assay results were categorized as negative or positive. A persistent positive result was defined as a positive post-Day 0 visit immunogenic response that occurred for at least 2 consecutive assessments or a single result at the final assessment. A transient positive result was defined as a single post-Day 0 visit positive immunogenic response that did not occur at the final assessment. Any time post-Day 0 visit data are reported (or post-Week 24 for Treatment Holiday - Restart phase). Day 0 visit date is defined as Day 0 from present study.
Time frame: Up to 52 weeks
Percentage Change From Baseline in Immunoglobulin
Serum samples were collected at indicated time-points for analysis of immunoglobulins: Immunoglobulin G (IgG), Immunoglobulin A (IgA), and Immunoglobulin M (IgM). Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (value at specified visit minus Baseline value) divided by Baseline value.
Time frame: Baseline (Day 0 from parent studies); Day 0 and 8, 16, 24, 32, 40, 48 and 52 weeks
Percentage Change From Baseline in Autoantibody:Anti-double Stranded Deoxyribonucleic Acid (dsDNA)
Blood samples were collected at indicated time-points for analysis of autoantibodies like dsDNA. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.
Time frame: Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks
Percentage Change From Baseline in Autoantibody: Antinuclear Antibody (ANA)
Blood samples were collected at indicated time-points for analysis of autoantibodies like ANA. Only participants who had an ANA value measured in INDEX at the parent studies Baseline were included in this analysis. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.
Time frame: Baseline (Day 0 from parent studies); Day 0 and 24 and 52 weeks
Percentage Change From Baseline in Complement Levels
Blood samples were collected at indicated time-points for analysis of complement levels like complement 3 (C3) and complement 4 (C4). Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.
Time frame: Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks
Percentage Change From Baseline in B Cell Subsets
Blood samples were collected at indicated time-points for analysis of Activated B cells subsets like Activated CD19+CD20+CD69+, cluster of differentiation 20+ (CD20+), Memory CD19+CD20+CD27+, Naive CD19+CD20+CD27-, Plasma CD19+CD20-CD138+, Plasmacytoid CD19+CD20+CD138+, and SLE Subset CD19+CD38b+CD27b+Lymph. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.
Time frame: Baseline (Day 0 from parent studies); Day 0 and 8, 16, 24, 32, 40 and 52 weeks
Percentage Change From 24 Week in B Cell Subsets: Treatment Holiday Group (Re-start Phase)
Blood samples were collected at indicated time-points for analysis of Activated B cells subsets like Activated CD19+CD20+CD69+, CD20+, Memory CD19+CD20+CD27+, Naive CD19+CD20+CD27-, Plasma CD19+CD20-CD138+, Plasmacytoid CD19+CD20+CD138+, and SLE Subset CD19+CD38b+CD27b+Lymph. Percentage change from Week 24 of present study was calculated as 100\*(value at specified visit - Week 24 value) divided by week 24 value. The data below is only reported for the Treatment Holiday Group (Re-start phase). Participants in this group restarted belimumab therapy one day after Week 24, hence the Baseline for this outcome measure was Week 24 visit. No other groups were measured for this outcome.
Time frame: Week 24, 32, 40 and 52 weeks
SELENA SLEDAI Scores Change From Baseline
SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, laboratory tests, and physician's assessment for each of 9 organ systems are given a weighted score and summed if present (marked 'Yes') at the time of the visit or in the preceding 10 days. The maximum theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 'No'). Data are reported at the specified time-points from Day 0 (of present study) up to Week 52. Baseline is defined as the Day 0 from parent studies. Change from Baseline is equal to (Value at specified visit minus Baseline value).
Time frame: Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48 and 52 weeks
Number of Days of Daily Prednisone Dose >=7.5 mg/Day and/or Increased by 25 Percent From Day 0 of This Study
All corticosteroids are converted to a prednisone equivalent average daily dose (mg/day). The average daily dose at Day 0 was used to assess the relative change in daily dose on a given day. The average daily dose at Day 0 was calculated as sum of the daily dose across all days from the Screening visit date up to and including Day 0 visit date divided by the number of days in the time period. Data reported are the median number of days on which the specified criteria was met for Day 0 to Week 24, Week 24 to Week 52, Day 0 to Week 52. For treatment holiday group, Day 0 to Week 24 corresponds to holiday phase, Week 24 to Week 52 corresponds to treatment Re-start phase.
Time frame: Day 0 to Week 24; Week 24 to Week 52; Day 0 to Week 52
Number of Days of Daily Prednisone Dose <=7.5 mg/Day and/or Decreased by 25 Percent From Day 0 of This Study
All corticosteroids are converted to a prednisone equivalent average daily dose (mg/day). The average daily dose at Day 0 was used to assess the relative change in daily dose on a given day. The average daily dose at Day 0 was calculated as sum of the daily dose across all days from the Screening visit date up to and including Day 0 visit date divided by the number of days in the time period. Data reported are the median number of days on which the specified criteria was met for Day 0 to Week 24, Week 24 to Week 52, Day 0 to Week 52. For treatment holiday group, Day 0 to Week 24 corresponds to holiday phase, Week 24 to Week 52 corresponds to treatment Re-start phase.
Time frame: Day 0 to Week 24; Week 24 to Week 52; Day 0 to Week 52
This was multi-center study to evaluate temporary discontinuation of belimumab 10 milligram(mg)/kilogram(kg) for 24 weeks followed by reintroduction of belimumab 10 mg/kg Intravenous (IV) for 28 weeks, in participants with low Systemic Lupus Erythematosus (SLE) disease activity receiving belimumab plus standard of care.
| Milestone | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group |
|---|---|---|---|
| Started | 39 | 29 | 12 |
| Completed | 33 | 27 | 11 |
| Not completed | 6 | 2 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Milestone | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group |
|---|---|---|---|
| Started | 0 | 16 | 10 |
| Completed | 0 | 6 | 3 |
| Not completed | 0 | 10 | 7 |
| Withdrew: Study terminated by sponsor | 0 | 10 | 7 |
SFI Flare was defined as a mild/moderate or severe flare according to the modified Safety of Estrogen in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) SLE Flare Index (modified excluded severe flares from the SELENA SLEDAI flare assessment that were triggered only by an increase in SELENA SLEDAI score to \>12).Time to first SFI flare is defined as the number of days from Day 0 visit date to the date the participant has a flare (event date - Day 0 visit date + 1) in the 52 Week/Holiday phase; (event date - treatment re-start date + 1) in the Re-start Holiday phase. Day 0 visit date is defined as Day 0 from present study. Median time to first SFI flare is reported; estimated using the product-limit method.
| Days | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| Median Time to First SLE Flare Index (SFI) | 183.0 (91.0 to 370.0) | NA (365.0 to NA) | NA (30.0 to NA) | NA (NA to NA) |
Rate per subject year of SFI flare was calculated as total number of flares divided by total subject years in interval. The total subject years for each participant was calculated as (Week 52/ Exit visit date minus Day 0 visit date + 1) for Long-term discontinuation and treatment control groups. For treatment holiday phase group the subject-years for each participant was calculated as (Week 24/Treatment Re-start/Exit visit date minus Day 0 Visit date + 1)/365.25. For re-start treatment holiday phase group the subject-years for each participant was calculated as (Week 52/Exit visit date minus Week 24/Treatment Re-start date + 1)/365.25. Day 0 visit date is defined as Day 0 from present study.
| Flares per Subject-year | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| Rate of SLE Index Flare Per Subject Year | 2.1 | 0.6 | 1.0 | 0.3 |
The SLE Flare Index categorizes SLE flare as "mild or moderate" or "severe" based on a positive assessment for at least 1 of 5 variables as follows: Change in SELENA SLEDAI score from the most recent assessment to current; Change in signs or symptoms of disease activity; Change in prednisone dosage; Use of new medications for disease activity or hospitalization; Change in Physician's Global Assessment (PGA) score; Hospitalization for SLE activity is an additional category included only for a severe flare. Time to first severe flare is defined as (event date-Day 0 visit date) + 1 for Long-term discontinuation, treatment control groups and holiday phase group. For holiday phase group data censored at last flare assessment by treatment re-start date. Time to first severe flare is defined as (event date-treatment re-start date) + 1 for Re-start treatment holiday group. Median time to first severe SFI flare is reported; estimated using the product-limit method.
| Days | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| Median Time to First Severe SFI Flare | NA (327.0 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Rebound is defined as SELENA SLEDAI score during the first 24 weeks that exceeds the Baseline SELENA SLEDAI score in the participant's respective original parent study. Baseline is defined as the Day 0 visit from the parent study. SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, laboratory tests, and physician's assessment for each of 9 organ systems are given a weighted score and summed if present (marked 'Yes') at the time of the visit or in the preceding 10 days. The maximum theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 'No'). Any time during the first 24 weeks of this study has been reported.
| Participants | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group |
|---|---|---|---|
| Number of Participants With Evidence of Rebound | 2 | 2 | 0 |
Immunogenicity assay results were categorized as negative or positive. A persistent positive result was defined as a positive post-Day 0 visit immunogenic response that occurred for at least 2 consecutive assessments or a single result at the final assessment. A transient positive result was defined as a single post-Day 0 visit positive immunogenic response that did not occur at the final assessment. Any time post-Day 0 visit data are reported (or post-Week 24 for Treatment Holiday - Restart phase). Day 0 visit date is defined as Day 0 from present study.
| Participants | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| Negative | 39 | 29 | 12 | 11 |
| Persistent positive | 0 | 0 | 0 | 0 |
| Transient positive | 0 | 0 | 0 | 0 |
Serum samples were collected at indicated time-points for analysis of immunoglobulins: Immunoglobulin G (IgG), Immunoglobulin A (IgA), and Immunoglobulin M (IgM). Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (value at specified visit minus Baseline value) divided by Baseline value.
| Percent change | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| IgA,Day 0,n=31,29, 12,0 | -19.205 (-38.406 to -7.229) | -25.909 (-35.168 to -16.901) | -22.193 (-33.468 to -14.278) | — |
| IgA,Week 8,n=37,29, 11,0 | -21.028 (-41.897 to -11.066) | -31.455 (-37.166 to -24.186) | -24.242 (-36.981 to -14.213) | — |
| IgA, Week 16,n=36,27, 11,0 | -22.052 (-39.715 to -8.880) | -31.016 (-36.676 to -23.432) | -20.202 (-38.381 to -4.975) | — |
| IgA, Week 24,n=31,27, 11,0 | -20.570 (-34.101 to 3.271) | -28.000 (-34.097 to -21.033) | -21.711 (-35.533 to 5.240) | — |
| IgA, Week 32,n=34,27,0,10 | -11.243 (-29.004 to 3.004) | -29.703 (-37.615 to -19.697) | — | -23.363 (-39.164 to -1.875) |
| IgA, Week 40,n=33,25,0,11 | -10.769 (-33.575 to 2.715) | -30.617 (-37.143 to -26.934) | — | -24.579 (-33.891 to 1.990) |
| IgA, Week 48,n=33,27,0,10 | -16.000 (-27.848 to 10.850) | -34.091 (-37.867 to -19.767) | — | -33.936 (-42.105 to 6.883) |
| IgA, Week 52,n=33,27,0,10 | -14.859 (-28.646 to 9.346) | -30.698 (-38.806 to -17.128) | — | -31.663 (-40.102 to 0.498) |
| IgG,Day 0,n=39,29, 12,0 | -13.939 (-35.349 to 3.571) | -29.524 (-35.645 to -14.872) | -19.481 (-33.330 to -9.757) | — |
| IgG,Week 8,n=37,29, 11,0 | -19.169 (-37.209 to -0.877) | -29.048 (-35.795 to -6.897) | -25.571 (-31.788 to -16.234) | — |
| IgG, Week 16,n=36,27, 11,0 | -16.169 (-37.881 to 8.306) | -29.818 (-35.714 to -5.172) | -21.642 (-29.870 to -18.721) | — |
| IgG, Week 24,n=31,27, 11,0 | -17.982 (-34.545 to 0.662) | -26.241 (-32.571 to -7.080) | -17.886 (-26.623 to -8.955) | — |
| IgG, Week 32,n=34,27,0,10 | -9.798 (-34.146 to 3.653) | -23.288 (-34.220 to -8.420) | — | -18.611 (-24.725 to -9.459) |
| IgG, Week 40,n=34,25,0,11 | -6.955 (-36.842 to 4.878) | -25.532 (-34.286 to -15.575) | — | -26.484 (-27.473 to -16.418) |
| IgG, Week 48,n=33,27,0,10 | -14.063 (-34.082 to 2.222) | -25.133 (-33.945 to -6.897) | — | -20.596 (-29.870 to -8.209) |
| IgG, Week 52,n=33,27,0,10 | -11.258 (-34.457 to 9.756) | -23.596 (-29.655 to -14.359) | — | -23.754 (-25.974 to -18.543) |
| IgM,Day 0,n=31,29, 12,0 | -47.059 (-67.333 to -26.761) | -53.608 (-64.583 to -41.463) | -44.326 (-63.895 to -25.516) | — |
| IgM,Week 8,n=37,29, 11,0 | -49.174 (-65.672 to -34.868) | -53.659 (-64.583 to -46.262) | -50.943 (-70.621 to -31.325) | — |
| IgM, Week 16,n=36,27, 11,0 | -50.077 (-61.922 to -30.099) | -54.945 (-61.224 to -43.103) | -45.926 (-70.690 to -19.277) | — |
| IgM, Week 24,n=31,27, 11,0 | -39.496 (-53.153 to -36.184) | -50.909 (-62.963 to -34.483) | -45.161 (-65.517 to -8.511) | — |
| IgM, Week 32,n=34,27,0,10 | -34.887 (-48.936 to -18.000) | -52.577 (-66.667 to -31.250) | — | -46.548 (-56.863 to -12.766) |
| IgM, Week 40,n=34,25,0,11 | -37.870 (-46.847 to -20.667) | -52.381 (-65.556 to -41.304) | — | -48.889 (-67.241 to -10.638) |
| IgM, Week 48,n=33,27,0,10 | -31.707 (-54.667 to -11.765) | -53.636 (-63.333 to -40.625) | — | -48.268 (-58.824 to -14.458) |
| IgM, Week 52,n=33,27,0,10 | -30.921 (-53.750 to -4.348) | -51.648 (-67.532 to -46.429) | — | -57.966 (-72.414 to -30.120) |
Blood samples were collected at indicated time-points for analysis of autoantibodies like dsDNA. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.
| Percent change | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| Day 0,n=39,29,12, 0 | -82.8 (-90.3 to -38.5) | -69.4 (-88.7 to -46.2) | -81.3 (-84.9 to -52.0) | — |
| Week 4,n=39,29,12, 0 | -82.8 (-92.2 to -46.1) | -65.9 (-89.0 to -53.8) | -83.2 (-90.0 to -51.6) | — |
| Week 8,n=37,29, 11,0 | -74.3 (-89.5 to -33.7) | -70.3 (-89.5 to -47.5) | -81.6 (-87.7 to -54.5) | — |
| Week 12,n=38,29, 11,0 | -77.3 (-89.1 to -28.2) | -68.9 (-90.1 to -50.0) | -85.0 (-88.6 to -53.0) | — |
| Week 16,n=36,27, 11,0 | -78.4 (-89.7 to -33.9) | -72.8 (-91.2 to -34.1) | -79.7 (-86.4 to -64.1) | — |
| Week 20,n=34,27, 11,0 | -82.8 (-90.3 to -33.7) | -70.3 (-91.9 to -50.0) | -79.9 (-88.3 to -55.2) | — |
| Week 24,n=31,27, 11,0 | -82.8 (-92.6 to -41.2) | -71.8 (-91.9 to -38.5) | -75.0 (-87.4 to -54.5) | — |
| Week 28,n=35,27,0,10 | -69.8 (-88.9 to -28.1) | -72.3 (-91.9 to -46.2) | — | -79.9 (-88.3 to -56.8) |
| Week 32,n=34,27,0,11 | -77.9 (-90.0 to -33.3) | -71.4 (-89.5 to -50.0) | — | -79.6 (-91.3 to -57.1) |
| Week 36,n=34,27,0,11 | -75.1 (-88.4 to -13.5) | -71.0 (-92.9 to -50.0) | — | -80.8 (-90.8 to -62.9) |
| Week 40,n=34,25,0,11 | -73.6 (-91.2 to -4.8) | -87.4 (-93.7 to -70.2) | — | -79.9 (-90.1 to -53.2) |
| Week 44,n=34,27,0,10 | -62.0 (-90.3 to -21.4) | -77.7 (-94.0 to -52.3) | — | -82.5 (-91.1 to -50.0) |
| Week 48,n=33,27,0,10 | -71.8 (-90.3 to -21.4) | -76.6 (-92.8 to -50.0) | — | -80.6 (-86.4 to -63.3) |
| Week 52,n=33,27,0,10 | -65.3 (-91.7 to -15.9) | -78.3 (-91.5 to -38.5) | — | -79.5 (-91.1 to -64.3) |
Blood samples were collected at indicated time-points for analysis of autoantibodies like ANA. Only participants who had an ANA value measured in INDEX at the parent studies Baseline were included in this analysis. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.
| Percent change | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| Day 0,n=21,27, 10,0 | -15.044 (-29.716 to 4.193) | -24.938 (-58.221 to 0.000) | -32.336 (-47.741 to -26.843) | — |
| Week 24,n=20,26, 10,0 | 5.723 (-9.113 to 24.347) | -27.434 (-62.747 to 0.000) | -29.771 (-44.978 to -13.643) | — |
| Week 52,n=19,26,0,9 | -16.455 (-56.522 to 21.800) | -45.961 (-66.917 to -11.765) | — | -35.539 (-43.928 to -20.586) |
Blood samples were collected at indicated time-points for analysis of complement levels like complement 3 (C3) and complement 4 (C4). Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.
| Percent change | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| C3, Day 0,n=39,27,12, 0 | 10.3 (-4.5 to 42.9) | 7.2 (-6.8 to 35.8) | 32.1 (23.7 to 61.5) | — |
| C3, Week 4,n=39,29,12, 0 | 15.4 (-2.2 to 42.0) | 16.0 (-7.3 to 27.5) | 14.8 (-6.8 to 46.1) | — |
| C3,Week 8,n=37,29, 11,0 | 13.6 (4.3 to 38.3) | 19.8 (-1.0 to 40.6) | 31.4 (17.2 to 60.9) | — |
| C3,Week 12,n=38,29, 11,0 | 10.9 (-6.3 to 50.0) | 14.1 (5.2 to 39.1) | 30.4 (24.7 to 75.0) | — |
| C3,Week 16,n=36,27, 11,0 | 15.2 (-0.6 to 59.1) | 20.5 (0.0 to 46.7) | 32.2 (20.0 to 62.5) | — |
| C3,Week 20,n=34,27, 11,0 | 15.4 (-4.7 to 40.3) | 13.6 (-4.3 to 26.6) | 30.0 (18.3 to 70.3) | — |
| C3,Week 24,n=31,27, 11,0 | 17.3 (-7.0 to 41.0) | 19.8 (-1.3 to 58.9) | 44.2 (5.7 to 53.2) | — |
| C3,Week 28,n=35,27,0,10 | 15.8 (-10.0 to 36.4) | 15.4 (7.8 to 42.2) | — | 31.3 (12.6 to 57.7) |
| C3,Week 32,n=34,27,0,11 | 13.8 (0.0 to 53.7) | 21.6 (6.7 to 50.7) | — | 31.6 (16.0 to 69.2) |
| C3,Week 36,n=34,27,0,11 | 9.4 (-2.9 to 44.8) | 17.0 (-8.1 to 35.1) | — | 26.0 (11.7 to 67.3) |
| C3,Week 40,n=34,25,0,11 | 12.8 (-2.5 to 28.3) | 17.3 (3.1 to 39.7) | — | 41.8 (12.8 to 62.5) |
| C3,Week 44,n=34,27,0,10 | 14.1 (0.0 to 29.7) | 22.7 (-6.3 to 51.6) | — | 38.9 (23.0 to 75.0) |
| C3,Week 48,n=33,27,0,10 | 15.4 (-5.1 to 35.0) | 15.9 (-4.5 to 41.5) | — | 30.4 (13.8 to 82.7) |
| C3,Week 52,n=33,27,0,10 | 5.9 (-9.1 to 25.9) | 21.9 (3.5 to 32.8) | — | 36.5 (7.1 to 77.3) |
| C4, Day 0,n=39,27,12, 0 | 36.4 (-6.3 to 100.0) | 27.8 (11.1 to 128.6) | 70.8 (25.2 to 154.2) | — |
| C4, Week 4,n=39,29,12, 0 | 31.6 (10.0 to 100.0) | 47.4 (0.0 to 87.5) | 39.7 (6.7 to 110.4) | — |
| C4,Week 8,n=37,29, 11,0 | 37.5 (2.6 to 83.3) | 71.4 (11.8 to 105.6) | 58.3 (33.3 to 183.3) | — |
| C4,Week 12,n=38,29, 11,0 | 27.6 (4.5 to 122.2) | 68.4 (12.0 to 121.4) | 64.3 (16.7 to 200.0) | — |
| C4,Week 16,n=36,27, 11,0 | 35.4 (13.1 to 158.3) | 50.0 (17.4 to 114.3) | 41.7 (25.0 to 150.0) | — |
| C4,Week 20,n=34,27, 11,0 | 32.6 (4.2 to 114.3) | 64.3 (0.0 to 109.1) | 58.3 (17.6 to 166.7) | — |
| C4,Week 24,n=31,27, 11,0 | 34.8 (0.0 to 128.6) | 57.1 (15.8 to 125.0) | 66.7 (26.3 to 83.3) | — |
| C4,Week 28,n=35,27,0,10 | 31.3 (0.0 to 100.0) | 66.7 (8.0 to 100.0) | — | 50.6 (8.3 to 166.7) |
| C4,Week 32,n=34,27,0,11 | 27.6 (0.0 to 106.7) | 92.9 (21.7 to 128.6) | — | 58.3 (21.1 to 175.0) |
| C4,Week 36,n=34,27,0,11 | 29.2 (0.0 to 100.0) | 50.0 (11.1 to 116.7) | — | 58.3 (25.0 to 183.3) |
| C4,Week 40,n=34,25,0,11 | 32.1 (0.0 to 73.3) | 73.3 (29.4 to 112.5) | — | 58.3 (21.1 to 116.7) |
| C4,Week 44,n=34,27,0,10 | 20.5 (0.0 to 68.8) | 57.1 (12.0 to 116.7) | — | 60.7 (36.8 to 150.0) |
| C4,Week 48,n=33,27,0,10 | 31.3 (-5.9 to 60.0) | 64.3 (15.8 to 114.3) | — | 34.5 (10.5 to 100.0) |
| C4,Week 52,n=33,27,0,10 | 17.6 (-5.9 to 62.5) | 63.2 (-4.0 to 126.7) | — | 58.3 (0.0 to 133.3) |
Blood samples were collected at indicated time-points for analysis of Activated B cells subsets like Activated CD19+CD20+CD69+, cluster of differentiation 20+ (CD20+), Memory CD19+CD20+CD27+, Naive CD19+CD20+CD27-, Plasma CD19+CD20-CD138+, Plasmacytoid CD19+CD20+CD138+, and SLE Subset CD19+CD38b+CD27b+Lymph. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.
| Percent change | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| Memory CD19+CD20+CD27+, Day 0,n=16,2,8,0 | -69.0 (-80.9 to -58.9) | -76.1 (-80.0 to -72.2) | -43.2 (-55.0 to 68.3) | — |
| Memory CD19+CD20+CD27+, Week 8,n=15,2,5,0 | -73.7 (-85.0 to -60.0) | -78.9 (-80.0 to -77.8) | -50.0 (-71.4 to 50.0) | — |
| Memory CD19+CD20+CD27+,Week16,n=14,2,6,0 | -83.4 (-93.2 to -66.7) | -69.2 (-80.0 to -58.3) | -60.7 (-80.0 to 0.0) | — |
| Memory CD19+CD20+CD27+,Week24,n=13,2,6,0 | -86.7 (-93.3 to -78.3) | -59.7 (-69.4 to -50.0) | -65.0 (-71.4 to 0.0) | — |
| Memory CD19+CD20+CD27+,Week32,n=12,2,0,7 | -85.8 (-91.4 to -72.5) | -73.3 (-80.0 to -66.7) | — | -20.0 (-52.0 to 133.3) |
| Memory CD19+CD20+CD27+,Week40,n=13,2,0,7 | -80.0 (-84.2 to -73.9) | -65.6 (-70.0 to -61.1) | — | 0.0 (-48.0 to 83.3) |
| Memory CD19+CD20+CD27+,Week52,n=13,2,0,6 | -81.8 (-86.7 to -65.2) | -78.9 (-80.0 to -77.8) | — | -10.0 (-57.1 to 83.3) |
| Naive CD19+CD20+CD27-,Day 0,n=16,2,8,0 | -78.3 (-90.0 to -63.7) | -91.6 (-96.9 to -86.3) | -81.0 (-91.2 to -27.0) | — |
| Naive CD19+CD20+CD27-,Week 8,n=15,2,5,0 | -80.5 (-90.4 to -60.0) | -94.3 (-96.5 to -92.2) | -83.0 (-84.6 to -16.7) | — |
| Naive CD19+CD20+CD27-,Week16,n=14,2,6,0 | -76.4 (-89.9 to -58.1) | -89.6 (-96.9 to -82.4) | -81.0 (-92.3 to -10.6) | — |
| Naive CD19+CD20+CD27-,Week 24,n=13,2,6,0 | -45.7 (-90.3 to 38.1) | -92.9 (-95.6 to -90.2) | -54.2 (-71.4 to 34.8) | — |
| Naive CD19+CD20+CD27-,Week 32,n=12,2,0,7 | -39.8 (-68.6 to 93.3) | -92.2 (-96.1 to -88.2) | — | -73.5 (-91.8 to 47.0) |
| Naive CD19+CD20+CD27-,Week 40,n=13,2,0,7 | -6.8 (-56.0 to 208.6) | -92.6 (-96.9 to -88.2) | — | -68.4 (-91.2 to 10.6) |
| Naive CD19+CD20+CD27-,Week 52,n=13,2,0,6 | 17.1 (-36.8 to 104.9) | -92.7 (-95.2 to -90.2) | — | -77.9 (-94.3 to 13.6) |
| Plasma CD19+CD20-CD138+,Day0,n=11,2,8,0 | -96.2 (-100.0 to -75.6) | 45.8 (-98.7 to 190.3) | -56.7 (-78.4 to 19.8) | — |
| Plasma CD19+CD20-CD138+,Week8,n=10,2,7,0 | -100.0 (-100.0 to -98.3) | 752.7 (-96.0 to 1601.4) | -88.6 (-92.3 to -44.5) | — |
| Plasma CD19+CD20-CD138+, Week16,n=9,2,7,0 | -97.8 (-99.3 to -96.5) | 535.2 (-90.7 to 1161.1) | -53.5 (-95.0 to -37.8) | — |
| Plasma CD19+CD20-CD138+,Week24,n=9,2,7,0 | -88.8 (-99.6 to -74.3) | 68.9 (-95.5 to 233.3) | -79.1 (-88.6 to 844.5) | — |
| Plasma CD19+CD20-CD138+,Week32,n=9,2,0,7 | -76.0 (-85.9 to -34.1) | 182.5 (-99.0 to 463.9) | — | -41.3 (-93.7 to 87.3) |
| Plasma CD19+CD20-CD138+,Week40,n=9,2,0,7 | -53.4 (-80.9 to -13.2) | -9.0 (-100.0 to 81.9) | — | -86.5 (-95.7 to 362.8) |
| Plasma CD19+CD20-CD138+,Week52,n=9,2,0,6 | -75.5 (-93.7 to -37.9) | -43.8 (-100.0 to 12.5) | — | -53.8 (-91.1 to 60.4) |
| Plasmacytoid CD19+CD20+CD138+,Day 0,n=11,2,8,0 | -98.9 (-99.7 to -94.7) | 118.1 (-85.6 to 321.9) | -75.5 (-96.5 to -25.0) | — |
| Plasmacytoid CD19+CD20+CD138+,Week8,n=10,2,7,0 | -97.6 (-99.8 to -94.6) | 14.1 (-90.6 to 118.8) | -75.0 (-98.2 to 54.9) | — |
| Plasmacytoid CD19+CD20+CD138+,Week16,n=9,2,7,0 | -98.7 (-100.0 to -96.8) | 226.3 (-94.4 to 546.9) | -75.9 (-95.5 to 526.4) | — |
| Plasmacytoid CD19+CD20+CD138+,Week24,n=9,2,7,0 | -98.5 (-98.8 to -93.0) | -16.3 (-95.0 to 62.5) | -15.0 (-65.0 to 254.7) | — |
| Plasmacytoid CD19+CD20+CD138+,Week32,n=9,2,0,7 | -95.4 (-97.9 to -82.2) | -24.1 (-85.6 to 37.5) | — | -52.5 (-96.3 to 728.3) |
| Plasmacytoid CD19+CD20+CD138+,Week40,n=9,2,0,7 | -93.4 (-94.4 to -41.4) | -31.3 (-100.0 to 37.5) | — | 2.5 (-94.0 to 52.8) |
| Plasmacytoid CD19+CD20+CD138+,Week 52,n=9,2,0,6 | -96.1 (-98.5 to -73.9) | 202.5 (-91.9 to 496.9) | — | 32.2 (10.0 to 69.8) |
| SLE Subset CD19+CD38b+CD27b+Lymph,Day0,n=11,2,8,0 | -28.3 (-60.4 to 43.8) | -67.9 (-93.2 to -42.6) | -66.7 (-78.1 to 215.2) | — |
| SLE Subset CD19+CD38b+CD27b+Lymph,Week8,n=10,2,7,0 | -30.5 (-52.0 to 137.2) | -91.7 (-96.6 to -86.7) | -71.9 (-89.0 to 121.3) | — |
| SLE Subset CD19+CD38b+CD27b+Lymph,Week16,n=9,2,7,0 | 21.3 (-82.6 to 157.5) | -74.2 (-97.0 to -51.3) | -48.6 (-82.1 to 204.4) | — |
| SLE Subset CD19+CD38b+CD27b+Lymph,Week24,n=9,2,7,0 | 25.2 (-48.1 to 168.6) | -64.7 (-75.1 to -54.2) | 152.3 (18.0 to 485.1) | — |
| SLE Subset CD19+CD38b+CD27b+Lymph,Week32,n=9,2,0,7 | -8.4 (-75.9 to 135.1) | -37.5 (-82.8 to 7.8) | — | -4.6 (-93.8 to 305.8) |
| SLE Subset CD19+CD38b+CD27b+Lymph,Week40,n=9,2,0,7 | -8.5 (-24.5 to 87.2) | -66.3 (-90.6 to -42.1) | — | -24.6 (-85.3 to 450.6) |
| SLE Subset CD19+CD38b+CD27b+Lymph,Week52,n=9,2,0,6 | -23.5 (-54.0 to 20.1) | -81.4 (-85.9 to -77.0) | — | 0.7 (-40.8 to 383.0) |
| CD20+ Day 0,n=16,2,8,0 | -75.2 (-89.1 to -58.7) | -88.1 (-95.8 to -80.5) | -77.1 (-86.8 to -22.0) | — |
| CD20+ Week 8,n=15,2,5,0 | -79.9 (-89.1 to -58.0) | -91.0 (-95.8 to -86.2) | -80.9 (-81.5 to -11.1) | — |
| CD20+,Week16,n=14,2,6,0 | -75.4 (-90.5 to -58.7) | -84.3 (-96.2 to -72.4) | -80.4 (-90.8 to -9.7) | — |
| CD20+,Week24,n=13,2,6,0 | -52.0 (-90.9 to 26.3) | -87.7 (-93.7 to -81.6) | -53.4 (-71.3 to 31.9) | — |
| CD20+,Week32,n=12,2,0,7 | -49.0 (-74.1 to 62.4) | -87.4 (-95.4 to -79.3) | — | -66.2 (-90.1 to 54.2) |
| CD20+,Week40,n=13,2,0,7 | -15.2 (-60.0 to 145.6) | -86.6 (-96.2 to -77.0) | — | -59.1 (-88.7 to 16.7) |
| CD20+,Week52,n=13,2,0,6 | -12.0 (-45.0 to 88.1) | -89.8 (-94.6 to -85.1) | — | -71.8 (-92.7 to 19.4) |
| Activated CD19+CD20+CD69+,Day0, n=11,1,8,0 | -99.8 (-100.0 to -91.7) | -86.1 (-86.1 to -86.1) | -65.1 (-93.6 to -2.1) | — |
| Activated CD19+CD20+CD69+, Week8, n=10,1,7,0 | -99.6 (-100.0 to -98.2) | -97.1 (-97.1 to -97.1) | -76.3 (-100.0 to 2141.7) | — |
| Activated CD19+CD20+CD69+, Week16, n=9,1,7,0 | -98.9 (-99.4 to -98.3) | -93.4 (-93.4 to -93.4) | -72.3 (-98.9 to -22.9) | — |
| Activated CD19+CD20+CD69+,Week24, n=9,1,7,0 | -99.7 (-100.0 to -95.3) | -94.2 (-94.2 to -94.2) | -50.9 (-95.6 to 80.0) | — |
| Activated CD19+CD20+CD69+,Week32, n=9,1,0,7 | -98.0 (-99.8 to -97.4) | -86.9 (-86.9 to -86.9) | — | -54.5 (-74.1 to 975.0) |
| Activated CD19+CD20+CD69+, Week40, n=9,1,0,7 | -98.1 (-99.8 to -96.7) | -100.0 (-100.0 to -100.0) | — | -47.5 (-100.0 to -24.6) |
| Activated CD19+CD20+CD69+, Week52, n=9,1,0,6 | -96.9 (-99.3 to -93.6) | -100.0 (-100.0 to -100.0) | — | -27.4 (-57.5 to 50.0) |
Blood samples were collected at indicated time-points for analysis of Activated B cells subsets like Activated CD19+CD20+CD69+, CD20+, Memory CD19+CD20+CD27+, Naive CD19+CD20+CD27-, Plasma CD19+CD20-CD138+, Plasmacytoid CD19+CD20+CD138+, and SLE Subset CD19+CD38b+CD27b+Lymph. Percentage change from Week 24 of present study was calculated as 100\*(value at specified visit - Week 24 value) divided by week 24 value. The data below is only reported for the Treatment Holiday Group (Re-start phase). Participants in this group restarted belimumab therapy one day after Week 24, hence the Baseline for this outcome measure was Week 24 visit. No other groups were measured for this outcome.
| Percent change | Treatment Holiday Group - Re-start Phase |
|---|---|
| Memory CD19+CD20+CD27+, Week 32 | 100.0 (40.5 to 250.0) |
| Memory CD19+CD20+CD27+, Week 40 | 83.3 (48.3 to 366.7) |
| Memory CD19+CD20+CD27+,Week52 | 66.7 (12.4 to 233.3) |
| Naive CD19+CD20+CD27-,Week 32 | -19.0 (-58.8 to 31.1) |
| Naive CD19+CD20+CD27-,Week 40 | -12.5 (-61.8 to 7.7) |
| Naive CD19+CD20+CD27-,Week52 | -35.6 (-84.8 to -7.9) |
| Plasma CD19+CD20-CD138+,Week32 | -16.3 (-71.4 to 237.8) |
| Plasma CD19+CD20-CD138+, Week40 | -59.8 (-73.7 to 18.5) |
| Plasma CD19+CD20-CD138+,Week52 | -48.0 (-92.4 to 188.9) |
| Plasmacytoid CD19+CD20+CD138+,Week32 | -35.7 (-69.3 to 133.5) |
| Plasmacytoid CD19+CD20+CD138+,Week40 | -64.3 (-89.4 to -56.9) |
| Plasmacytoid CD19+CD20+CD138+,Week52 | -55.0 (-72.7 to -52.1) |
| SLE SubsetCD19+CD38b+CD27b+Lymph,Week32 | -55.4 (-71.6 to -27.2) |
| SLE SubsetCD19+CD38b+CD27b+Lymph,Week40 | -56.9 (-75.3 to -0.7) |
| SLE SubsetCD19+CD38b+CD27b+Lymph,Week52 | -67.2 (-79.7 to -41.0) |
| CD20+, Week 32 | -3.3 (-45.2 to 29.7) |
| CD20+, Week 40 | 2.2 (-51.4 to 17.4) |
| CD20+, Week 52 | -20.0 (-78.9 to 30.8) |
| Activated CD19+CD20+CD69+,Week32 | -28.8 (-75.8 to 64.7) |
| Activated CD19+CD20+CD69+,Week40 | -23.8 (-88.1 to 191.2) |
| Activated CD19+CD20+CD69+,Week52 | -66.7 (-89.0 to 87.7) |
SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, laboratory tests, and physician's assessment for each of 9 organ systems are given a weighted score and summed if present (marked 'Yes') at the time of the visit or in the preceding 10 days. The maximum theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 'No'). Data are reported at the specified time-points from Day 0 (of present study) up to Week 52. Baseline is defined as the Day 0 from parent studies. Change from Baseline is equal to (Value at specified visit minus Baseline value).
| Scores on a scale | Long-term Discontinuation | Treatment Control Group | Treatment Holiday Group - Holiday Phase | Treatment Holiday Group - Re-start Phase |
|---|---|---|---|---|
| Day 0,n=39,29,12, 0 | -6.2 ± 4.12 | -6.9 ± 3.62 | -6.3 ± 4.31 | — |
| Week 4,n=39,29,12, 0 | -5.9 ± 5.07 | -6.6 ± 3.44 | -6.1 ± 4.01 | — |
| Week 8,n=38,29, 11,0 | -6.4 ± 4.18 | -7.0 ± 3.73 | -5.9 ± 4.16 | — |
| Week 12,n=38,29, 11,0 | -6.1 ± 4.28 | -7.0 ± 3.75 | -6.3 ± 3.95 | — |
| Week 16,n=36,27, 11,0 | -6.4 ± 5.21 | -6.8 ± 4.05 | -6.1 ± 3.96 | — |
| Week 20,n=36,27, 11,0 | -6.9 ± 4.17 | -6.9 ± 3.23 | -6.1 ± 3.96 | — |
| Week 24,n=36,27, 11,0 | -6.4 ± 4.45 | -6.7 ± 3.45 | -5.4 ± 4.01 | — |
| Week 28,n=35,27,0,10 | -5.8 ± 4.22 | -7.0 ± 3.32 | — | -5.5 ± 5.36 |
| Week 32,n=34,27,0,11 | -5.7 ± 4.59 | -7.1 ± 3.38 | — | -6.1 ± 4.01 |
| Week 36,n=34,27,0,11 | -5.0 ± 4.42 | -6.7 ± 3.59 | — | -5.9 ± 4.01 |
| Week 40,n=34,27,0,11 | -5.2 ± 4.30 | -7.2 ± 3.37 | — | -6.6 ± 4.30 |
| Week 44,n=34,27,0,11 | -5.8 ± 4.15 | -7.3 ± 3.49 | — | -6.3 ± 4.65 |
| Week 48,n=33,27,0,11 | -5.7 ± 4.30 | -7.3 ± 3.28 | — | -6.1 ± 3.91 |
| Week 52,n=33,27,0,11 | -5.0 ± 4.39 | -6.9 ± 3.69 | — | -5.5 ± 4.08 |
All corticosteroids are converted to a prednisone equivalent average daily dose (mg/day). The average daily dose at Day 0 was used to assess the relative change in daily dose on a given day. The average daily dose at Day 0 was calculated as sum of the daily dose across all days from the Screening visit date up to and including Day 0 visit date divided by the number of days in the time period. Data reported are the median number of days on which the specified criteria was met for Day 0 to Week 24, Week 24 to Week 52, Day 0 to Week 52. For treatment holiday group, Day 0 to Week 24 corresponds to holiday phase, Week 24 to Week 52 corresponds to treatment Re-start phase.
| Days | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group |
|---|---|---|---|
| Day 0 to Week 24, n=11, 12, 6 | 143.0 (3 to 173) | 170.0 (67 to 175) | 168.0 (61 to 170) |
| Day 0 to Week 52, n=13, 12, 6 | 278.0 (5 to 369) | 364.0 (145 to 392) | 364.0 (250 to 366) |
| Week 24 to Week 52, n=10, 9, 5 | 167.5 (1 to 201) | 196.0 (189 to 217) | 196.0 (194 to 196) |
All corticosteroids are converted to a prednisone equivalent average daily dose (mg/day). The average daily dose at Day 0 was used to assess the relative change in daily dose on a given day. The average daily dose at Day 0 was calculated as sum of the daily dose across all days from the Screening visit date up to and including Day 0 visit date divided by the number of days in the time period. Data reported are the median number of days on which the specified criteria was met for Day 0 to Week 24, Week 24 to Week 52, Day 0 to Week 52. For treatment holiday group, Day 0 to Week 24 corresponds to holiday phase, Week 24 to Week 52 corresponds to treatment Re-start phase.
| Days | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group |
|---|---|---|---|
| Day 0 to Week 24, n=23,19, 6 | 168.0 (23 to 181) | 168.0 (26 to 175) | 166.0 (49 to 170) |
| Day 0 to Week 52, n=25,19, 6 | 362.0 (23 to 385) | 364.0 (91 to 391) | 364.0 (49 to 370) |
| Week 24 to Week 52, n=24,18, 5 | 195.0 (1 to 208) | 196.0 (189 to 225) | 200.0 (189 to 203) |
Collected over Non-serious adverse events and serious adverse events (SAE) were collected up to 52 weeks for all treatment groups. For Treatment Control and Treatment Holiday Re-start, it also included 16 weeks follow up after the last dose of belimumab for participants who did not continue in Maintenance phase. For Maintenance phase, non-SAE and SAE were collected until Week 48 of subsequent years (Maintenance is Year 2, 3, 4) and includes 16 weeks follow up after last dose of belimumab.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Phase: Long-term Discontinuation Group | 0/39 (0%) | 6/39 (15.4%) | 30/39 (76.9%) |
| Treatment Phase: Treatment Control Group | 0/29 (0%) | 2/29 (6.9%) | 18/29 (62.1%) |
| Treatment Phase: Treatment Holiday Group - Holiday Phase | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Treatment Phase: Treatment Holiday Group - Re-start Phase | 0/11 (0%) | 1/11 (9.1%) | 9/11 (81.8%) |
| Maintenance Phase: Treatment Control | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Maintenance Phase: Treatment Holiday | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Event | Treatment Phase: Long-term Discontinuation Group | Treatment Phase: Treatment Control Group | Treatment Phase: Treatment Holiday Group - Holiday Phase | Treatment Phase: Treatment Holiday Group - Re-start Phase | Maintenance Phase: Treatment Control | Maintenance Phase: Treatment Holiday |
|---|---|---|---|---|---|---|
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/39 | 0/29 | 0/12 | 1/11 | 0/16 | 0/10 |
| Lupus nephritisRenal and urinary disorders | 2/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Upper respiratory tract infectionInfections and infestations | 0/39 | 1/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/39 | 1/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Skin lacerationInjury, poisoning and procedural complications | 0/39 | 1/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Diarrhoea infectiousInfections and infestations | 1/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Pneumonia pseudomonalInfections and infestations | 1/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| SepsisInfections and infestations | 1/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Pericarditis lupusCardiac disorders | 1/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Generalised oedemaGeneral disorders | 1/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Event | Treatment Phase: Long-term Discontinuation Group | Treatment Phase: Treatment Control Group | Treatment Phase: Treatment Holiday Group - Holiday Phase | Treatment Phase: Treatment Holiday Group - Re-start Phase | Maintenance Phase: Treatment Control | Maintenance Phase: Treatment Holiday |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 10/39 | 5/29 | 1/12 | 4/11 | 2/16 | 4/10 |
| HypokalaemiaMetabolism and nutrition disorders | 1/39 | 2/29 | 1/12 | 2/11 | 0/16 | 0/10 |
| Upper respiratory tract infectionInfections and infestations | 5/39 | 2/29 | 2/12 | 1/11 | 2/16 | 1/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/39 | 2/29 | 1/12 | 0/11 | 0/16 | 0/10 |
| ArthritisMusculoskeletal and connective tissue disorders | 4/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| FatigueGeneral disorders | 4/39 | 0/29 | 0/12 | 0/11 | 0/16 | 0/10 |
| Upper respiratory tract infection bacterialInfections and infestations | 3/39 | 0/29 | 0/12 | 0/11 | 0/16 | 1/10 |
| CystitisInfections and infestations | 0/39 | 1/29 | 0/12 | 1/11 | 0/16 | 1/10 |
| GastroenteritisInfections and infestations | 1/39 | 0/29 | 0/12 | 1/11 | 0/16 | 1/10 |
| Age, Continuous(Years) | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group | Total |
|---|---|---|---|---|
| Mean | 38.9 ± 12.01 | 40.6 ± 9.76 | 38.1 ± 8.04 | 39.4 ± 10.63 |
| Sex: Female, Male(Participants) | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group | Total |
|---|---|---|---|---|
| Female | 35 | 27 | 9 | 71 |
| Male | 4 | 2 | 3 | 9 |
| Race/Ethnicity, Customized(Participants) | Long-term Discontinuation Group | Treatment Control Group | Treatment Holiday Group | Total |
|---|---|---|---|---|
| White/Caucasian/European Heritage | 9 | 0 | 0 | 9 |
| Asian: Central/South Asian Heritage | 1 | 0 | 0 | 1 |
| Asian: East Asian Heritage | 23 | 27 | 4 | 54 |
| Asian: Japanese Heritage | 0 | 2 | 8 | 10 |
| African American/African Heritage | 5 | 0 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2014 to primary completion in Dec 2018, 55 months.
Results were first posted in Jan 2020, 1 year 1 month after primary completion.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 55 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →